Hospital registry of neuroendocrine tumors in N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- Authors: Komarova L.E.1, Arion A.I1, Tabolinovskaya T.D1, Pirogova N.A1, Orel N.F1, Solovyeva O.N1, Machaladze Z.O1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 21, No 6 (2016)
- Pages: 312-318
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40321
- DOI: https://doi.org/10.18821/1028-9984-2016-21-6-312-318
- ID: 40321
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Lyudmila E. Komarova
N.N. Blokhin Russian Cancer Research Center
Email: orgotdel@ronc.ru
MD, PhD, DSc, Prof., Head of the Scientific and Organizational Department of the N.N. Blokhin Russian Cancer Research Center Moscow, 115478, Russian Federation
A. I Arion
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
T. D Tabolinovskaya
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
N. A Pirogova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
N. F Orel
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
O. N Solovyeva
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
Z. O Machaladze
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
References
- Muir C.S., Demaret E., Boyle P. The cancer registry in cancer control: an overview. In: The Role of the Registry in Cancer Control / Eds. D.M. Parkin, G. Wagner, C.S. Muir. Lyon: IARC Scientific Publications; 1985; no 6: 13-26.
- Yao J.C., Hassan M., Phan A. et al. One hundred years after «carcinoid» epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008; 26: 3063-72.
- Modlin I.M., Kidd M., Latich I., Zikusoka M.N., Shapiro M.D. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128: 1717-51.
- Hauso O., Gustafsson B.I., Kidd M., Waldum H.L., Drozdov I., Chan A.K. et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655-64.
- Fraenkel M., Kim M., Faggiano A. et al. Incidence and geographic distribution of gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). A systematic review of the literature. In 10-th Annual Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 6-8 March 2013, Barcelona. Spain. Barcelona; 2013: 47.
- Горбунова В.А. Современные аспекты диагностики и лечения онкологических заболеваний. В кн.: Избранные статьи из газеты «Медицинский вестник» и журнала i Doctor. Москва; 2014: 44-9.
- Garcia-Carbonero R., Capdevila J., Grespo-Herrero G. et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 2010; 21: 1794-803.
- Pavel M., Baudin E., Convelard A. et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95(2): 157-76.
- Godwin J.D. Carcinoid tumors. An analysis of 2837 cases. Cancer. 1975; 36: 560-9.
- WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 2015: 63.
- Karac H., Erol O., Ulas A. et al. A Multi - Centre Retrospective Evaluation of Neuroendocrine Tumors. (Anatolian Society of Medical Oncology Group Study). In: 10-th Annual Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 6-8 March 2013, Barcelona, Spain. Barcelona, 2013: 51.
- Yalching M., Garcia-Hernandez J. et al. Epidemiological characteristics from a single Centre Database. Cohort of 1301 neuroendocrine tumor patients: Is there an association between age and grade of NETs? In: 12th Annual Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. 11-13 March 2015, Barcelona, Spain. Barcelona; 2015: 71.
- Niederle M.B., Hackl M., Kaserer K. et al. Gastroenteropancreatic neuroendocrine Tymors: the current incidence and staging based on the WHO and European Neuroendocrine Tumors Society classification: an analysis dased on prospectively collected parameters. Endocr. Cancer. 2010; 17; 909-18.
- Бохян В.Ю. Нейроэндокринные опухоли (карциноиды) желудка. В кн.: Материалы 2-й Российской конференции по нейроэндокринным опухолям. Москва, 2014: 67-82.
- Klimstra D., Arnold R., Capella C. et al. Neuroendocrine neoplasms of the pancreas. In: WHO Classification of Tumors of the Digestive System. 4th Ed. / Eds. F.T. Bosman et al. Lyon: IARC; 2010; Ch. 12: 322-6.
- Ramage J.K., Davies A.H., Ardill J. et al. UKNETwork for neuroendocrine tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005; 54 (Suppl. 4): iv1-16.
- Горбунова В.А., Орёл Н.Ф., Егоров Г.Н. Редкие опухоли APUD - системы (карциноиды) и нейроэндокринные опухоли поджелудочной железы. Клиника диагностика, лечение. М.; 1999: 27-8.
- Горбунова В.А. Нейроэндокринные опухоли гастроинтестинального тракта и поджелудочной железы. В кн. Рациональная фармакотерапия в онкологии. Репринт / Под общей ред. акад. РАН М.И. Давыдова, проф. В.А. Горбуновой. М.: Литтерра; 2015: 2-9.
- Valle J.W., Eatock M., Clueit B. et al. A systematic review of non-surgical treatment for pancreatic neuroendocrine tumours. Cancer Treat. Rev. 2014; 40(3): 376-89.
- Pape U.F., Bohming M., Berndt U., Tiling N., Wiedenmann B., Plockinger U. Survival and clinical outcome of patients with neuroendocrine tumors of the gastropancreatic track in German referral centre. Ann. N. Y. Acad. Sci. 2004; 1014: 222-33.
- Делекторская В.В., Павловская А.И. Морфологическая характеристика основных типов нейроэндокринных опухолей. Вестник Московского онкологического общества. 2010; 10. http:.www.oncology.ru/moa/vestnik/571/
- Емельянова Г.С., Маркович А.А., Кузьминов А.Е., Орел Н.Ф., Горбунова В.А. Применение отечественного аналога пролонгированного соматостатического октреотида (октреотид-депо TM) в дозе 20-40 мг у пациентов с нейроэндокринными опухолями (опыт отделения химиотерапии РОНЦ). В кн.: Рациональная фармакотерапия в онкологии. Репринт /Под общей ред. акад. РАН М.И. Давыдова, проф. В.А. Горбуновой. М.: Литтерра. 2015: 10-1.